Cardiovascular Diseases Associated with Pregnancy: Early Assessment Using Non-Invasive MicroRNA Profiling

Research output: Contribution to journalArticle

19 Downloads (Pure)

Abstract

In some cases pregnancies are associated with severe cases of cardiovascular diseases (CVDs). The early detection and proper treatment of CVDs during maternity is detrimental to the health outcome and wellbeing of both mother and child. Unfortunately, both the detection rate and assessment of CVDs during pregnancies are unsatisfactory.
Currently, the messenger RNA (mRNA) regulators called microRNAs (miRNAs) are being extensively profiled for use as clinical CVDs biomarkers due to their specific tissue and disease expression signature profiles. The identification and development of reliable biomarkers for early clinical assessment of CVDs during pregnancy could allow the detection of sub-clinical cardiac injury risk in vulnerable pregnant patients before irreversible damage occurs. CVDs specific miRNA biomarkers could provide the clinicians with a valuable tool to allow prognosis of patients at risk of cardiovascular injury and the introduction of therapy and intervention in order to increase health outcome and survival rate of both the mother and child.
Original languageEnglish
Article number1000212
Number of pages4
JournalClinics in Mother and Child Health
Volume12
Issue number4
DOIs
Publication statusPublished - 19 Dec 2015

Fingerprint

MicroRNAs
Cardiovascular Diseases
Pregnancy
Biomarkers
Mothers
Health
Wounds and Injuries
Survival Rate
Messenger RNA
Therapeutics

Bibliographical note

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Keywords

  • Pregnancy associated cardiovascular diseases
  • Classification of cardiovascular diseases
  • Peripartum cardiomyopathy
  • Risk factors
  • MicroRNAs

Cite this

@article{c8952685a1284faa9f8185c696982031,
title = "Cardiovascular Diseases Associated with Pregnancy: Early Assessment Using Non-Invasive MicroRNA Profiling",
abstract = "In some cases pregnancies are associated with severe cases of cardiovascular diseases (CVDs). The early detection and proper treatment of CVDs during maternity is detrimental to the health outcome and wellbeing of both mother and child. Unfortunately, both the detection rate and assessment of CVDs during pregnancies are unsatisfactory.Currently, the messenger RNA (mRNA) regulators called microRNAs (miRNAs) are being extensively profiled for use as clinical CVDs biomarkers due to their specific tissue and disease expression signature profiles. The identification and development of reliable biomarkers for early clinical assessment of CVDs during pregnancy could allow the detection of sub-clinical cardiac injury risk in vulnerable pregnant patients before irreversible damage occurs. CVDs specific miRNA biomarkers could provide the clinicians with a valuable tool to allow prognosis of patients at risk of cardiovascular injury and the introduction of therapy and intervention in order to increase health outcome and survival rate of both the mother and child.",
keywords = "Pregnancy associated cardiovascular diseases, Classification of cardiovascular diseases, Peripartum cardiomyopathy, Risk factors, MicroRNAs",
author = "Hardip Sandhu",
note = "This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.",
year = "2015",
month = "12",
day = "19",
doi = "10.4172/2090-7214.1000212",
language = "English",
volume = "12",
journal = "Clinics in Mother and Child Health",
issn = "1812-5840",
publisher = "Omics Publishing Group",
number = "4",

}

TY - JOUR

T1 - Cardiovascular Diseases Associated with Pregnancy

T2 - Early Assessment Using Non-Invasive MicroRNA Profiling

AU - Sandhu, Hardip

N1 - This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

PY - 2015/12/19

Y1 - 2015/12/19

N2 - In some cases pregnancies are associated with severe cases of cardiovascular diseases (CVDs). The early detection and proper treatment of CVDs during maternity is detrimental to the health outcome and wellbeing of both mother and child. Unfortunately, both the detection rate and assessment of CVDs during pregnancies are unsatisfactory.Currently, the messenger RNA (mRNA) regulators called microRNAs (miRNAs) are being extensively profiled for use as clinical CVDs biomarkers due to their specific tissue and disease expression signature profiles. The identification and development of reliable biomarkers for early clinical assessment of CVDs during pregnancy could allow the detection of sub-clinical cardiac injury risk in vulnerable pregnant patients before irreversible damage occurs. CVDs specific miRNA biomarkers could provide the clinicians with a valuable tool to allow prognosis of patients at risk of cardiovascular injury and the introduction of therapy and intervention in order to increase health outcome and survival rate of both the mother and child.

AB - In some cases pregnancies are associated with severe cases of cardiovascular diseases (CVDs). The early detection and proper treatment of CVDs during maternity is detrimental to the health outcome and wellbeing of both mother and child. Unfortunately, both the detection rate and assessment of CVDs during pregnancies are unsatisfactory.Currently, the messenger RNA (mRNA) regulators called microRNAs (miRNAs) are being extensively profiled for use as clinical CVDs biomarkers due to their specific tissue and disease expression signature profiles. The identification and development of reliable biomarkers for early clinical assessment of CVDs during pregnancy could allow the detection of sub-clinical cardiac injury risk in vulnerable pregnant patients before irreversible damage occurs. CVDs specific miRNA biomarkers could provide the clinicians with a valuable tool to allow prognosis of patients at risk of cardiovascular injury and the introduction of therapy and intervention in order to increase health outcome and survival rate of both the mother and child.

KW - Pregnancy associated cardiovascular diseases

KW - Classification of cardiovascular diseases

KW - Peripartum cardiomyopathy

KW - Risk factors

KW - MicroRNAs

U2 - 10.4172/2090-7214.1000212

DO - 10.4172/2090-7214.1000212

M3 - Article

VL - 12

JO - Clinics in Mother and Child Health

JF - Clinics in Mother and Child Health

SN - 1812-5840

IS - 4

M1 - 1000212

ER -